NO995109D0 - Formuleringer inneholdende 1,2,4-benzotriazinoksyder - Google Patents

Formuleringer inneholdende 1,2,4-benzotriazinoksyder

Info

Publication number
NO995109D0
NO995109D0 NO995109A NO995109A NO995109D0 NO 995109 D0 NO995109 D0 NO 995109D0 NO 995109 A NO995109 A NO 995109A NO 995109 A NO995109 A NO 995109A NO 995109 D0 NO995109 D0 NO 995109D0
Authority
NO
Norway
Prior art keywords
formulations containing
benzotriazine oxides
benzotriazine
oxides
treatment
Prior art date
Application number
NO995109A
Other languages
English (en)
Other versions
NO995109L (no
NO325275B1 (no
Inventor
Stephen Brown
Edward Baker
Original Assignee
Sanofi Synthelabo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo Inc filed Critical Sanofi Synthelabo Inc
Publication of NO995109D0 publication Critical patent/NO995109D0/no
Publication of NO995109L publication Critical patent/NO995109L/no
Publication of NO325275B1 publication Critical patent/NO325275B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
NO19995109A 1997-04-21 1999-10-20 Vandige formuleringer for behandling av krefttumorer samt anvendelse derav. NO325275B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/837,637 US5827850A (en) 1995-09-25 1997-04-21 1,2,4-benzotriazine oxides formulations
PCT/US1998/007391 WO1998047512A1 (en) 1997-04-21 1998-04-14 1,2,4-benzotriazine oxides formulations

Publications (3)

Publication Number Publication Date
NO995109D0 true NO995109D0 (no) 1999-10-20
NO995109L NO995109L (no) 1999-12-21
NO325275B1 NO325275B1 (no) 2008-03-17

Family

ID=25275027

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19995109A NO325275B1 (no) 1997-04-21 1999-10-20 Vandige formuleringer for behandling av krefttumorer samt anvendelse derav.

Country Status (13)

Country Link
US (2) US5827850A (no)
EP (1) EP1044005B1 (no)
JP (1) JP2001523248A (no)
AT (1) ATE332139T1 (no)
AU (1) AU6969098A (no)
BR (1) BR9808958A (no)
CA (1) CA2287257C (no)
DE (1) DE69835167T8 (no)
DK (1) DK1044005T3 (no)
ES (1) ES2267183T3 (no)
NO (1) NO325275B1 (no)
PT (1) PT1044005E (no)
WO (1) WO1998047512A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624925A (en) * 1986-09-25 1997-04-29 Sri International 1,2,4-benzotriazine oxides as radiosensitizers and selective cytotoxic agents
NZ521436A (en) * 2002-09-17 2005-07-29 Auckland Uniservices Ltd DNA- targeted benzotriazine 1,4-dioxides and their use in cancer therapy
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
CA2456569A1 (en) * 2003-03-14 2004-09-14 Auckland Uniservices Limited Benzoazine mono-n-oxides and benzoazine 1,4 dioxides and compositions therefrom for the therapeutic use in cancer treatments
AU2005231507B2 (en) 2004-04-08 2012-03-01 Targegen, Inc. Benzotriazine inhibitors of kinases
US7652051B2 (en) 2004-08-25 2010-01-26 Targegen, Inc. Heterocyclic compounds and methods of use
US7834178B2 (en) * 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
CN101683346B (zh) * 2008-09-24 2015-04-01 杭州民生药业有限公司 一种替拉扎明非肠道含水制剂及其制备方法
CN101683319B (zh) * 2008-09-24 2012-09-05 杭州民生药业有限公司 一种替拉扎明非肠道给药含水制剂及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001410A (en) * 1972-02-01 1977-01-04 Bayer Aktiengesellschaft 3-amino-1,2,4-benzotriazine-1,4-di-n-oxide compositions and method of using same
US3980779A (en) * 1972-02-01 1976-09-14 Bayer Aktiengesellschaft 3-Amino-1,2,4-benzotriazine-1,4-di-N-oxide compositions and method of using same
US5175287A (en) * 1986-09-25 1992-12-29 S R I International Process for preparing 1,2,4-benzotriazine oxides
KR100514009B1 (ko) * 1995-09-25 2005-11-25 사노피-신쎄라보 인코포레이티드 1,2,4-벤조트리아진옥사이드제제

Also Published As

Publication number Publication date
DE69835167T8 (de) 2007-12-06
NO995109L (no) 1999-12-21
US6153610A (en) 2000-11-28
EP1044005B1 (en) 2006-07-05
WO1998047512A1 (en) 1998-10-29
EP1044005A1 (en) 2000-10-18
AU6969098A (en) 1998-11-13
PT1044005E (pt) 2006-10-31
DK1044005T3 (da) 2006-09-25
US5827850A (en) 1998-10-27
BR9808958A (pt) 2000-08-01
NO325275B1 (no) 2008-03-17
CA2287257A1 (en) 1998-10-29
ES2267183T3 (es) 2007-03-01
ATE332139T1 (de) 2006-07-15
DE69835167D1 (de) 2006-08-17
DE69835167T2 (de) 2007-06-06
CA2287257C (en) 2007-06-12
JP2001523248A (ja) 2001-11-20
EP1044005A4 (en) 2001-08-08

Similar Documents

Publication Publication Date Title
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
IL100942A0 (en) 2,4-diaminoquinazoline derivatives for enhancing antitumor activity
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
IL99906A0 (en) Quinazoline derivatives for enhancing antitumor activity
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
ITMI990375A1 (it) Trattamento del cancro co epotiloni
NO20026245D0 (no) Forbedring av antistoff-cytokin-fusjonsprotein-formidlede immunresponser ved kombinert behandling med immunocytokin-opptaksökende midler
NO993654L (no) Kit for Õ inhibere cancervekst, omfattende et kjemoterapeutisk middel og et benzimidazol og eventuelt en forsterker
DE60041333D1 (de) Hen prostatkrebs exprimiert wird, und deren verwendungen
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
NO995109D0 (no) Formuleringer inneholdende 1,2,4-benzotriazinoksyder
MXPA03003011A (es) Metodos para inducir muerte de celulas cancerosas y regresion de tumores.
DK0972782T3 (da) Monoklonalt antistof, der genkender oligosaccharidet N-glycolyleret galactose-glucose-sialinsyre i maligne tumorer, og præparater, der indeholder det
MY137303A (en) Methods for treating proliferative diseases
IL142340A0 (en) Methods for identification, diagnosis, and treatment of breast cancer
EP1364657A4 (en) REMEDIES AGAINST TUMORS AFFECTING HEMATOPOIETIC BODIES
ZA982136B (en) Novel carboxylic acid derivatives, their preparation and use in treating cancer.
CA2232989A1 (en) 1,2,4-benzotriazine oxides formulations
SE0100684D0 (sv) New subject-matter
WO2001053524A3 (en) Cancer associated genes and their products
AU5302599A (en) Method for diagnosing bone metastasis of malignant tumor
ZA200203166B (en) Treatment of cancer.
GB9723824D0 (en) Cytostatic agents